Maximal tumor diameter in the preoperative tumor magnetic resonance imaging (MRI) T2 image is associated with prognosis of Grade II Glioma.

作者: Guangying Zhang , Haipeng Liu , Xinqiong Huang , Liangfang Shen

DOI: 10.1097/MD.0000000000024850

关键词:

摘要: ABSTRACT Factors associated with the prognosis of low-grade glioma remain undefined. In this study, we examined whether maximal tumor diameter in preoperative magnetic resonance imaging (MRI) T2 image is grade II gliomas patients, aiming to provide insights into clinical prediction patient outcome.We retrospectively analyzed data patients Grade glioma, who were hospitalized Xiangya Hospital, Central South University, from 2011 2016. Kaplan-Meier and Cox proportional hazards analyses performed determine association between prognosis.A total 90 included study. Mean age was 37.7 ± 13.0 years, 58.9% them male. survival analysis overall (overall [OS], P = .009) event-free (EFS, P = .002) revealed statistically significant differences lesion <7 cm those ≥7 cm. The MRI identified as a prognostic factor OS (P = .013), while constituting an independent risk for EFS (P = .002) alongside elevated histological after recurrence (P = .006).The independently predicts glioma.

参考文章(27)
Priya Kumthekar, Jeffrey Raizer, Simran Singh, Low-grade glioma. Cancer treatment and research. ,vol. 163, pp. 75- 87 ,(2015) , 10.1007/978-3-319-12048-5_5
Cancer Genome Atlas Research Network, None, Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. The New England Journal of Medicine. ,vol. 372, pp. 2481- 2498 ,(2015) , 10.1056/NEJMOA1402121
A TROTTI, A COLEVAS, A SETSER, V RUSCH, D JAQUES, V BUDACH, C LANGER, B MURPHY, R CUMBERLIN, C COLEMAN, CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Seminars in Radiation Oncology. ,vol. 13, pp. 176- 181 ,(2003) , 10.1016/S1053-4296(03)00031-6
Bela Purohit, Ali A. Kamli, Spyros S. Kollias, Imaging of adult brainstem gliomas European Journal of Radiology. ,vol. 84, pp. 709- 720 ,(2015) , 10.1016/J.EJRAD.2014.12.025
David Schiff, Low-grade gliomas Journal of Neurosurgery. ,vol. 115, pp. 945- 947 ,(2011) , 10.3171/2011.4.JNS11521
Elizabeth B. Claus, Kyle M. Walsh, John K. Wiencke, Annette M. Molinaro, Joseph L. Wiemels, Joellen M. Schildkraut, Melissa L. Bondy, Mitchel Berger, Robert Jenkins, Margaret Wrensch, Survival and low-grade glioma: the emergence of genetic information. Neurosurgical Focus. ,vol. 38, ,(2015) , 10.3171/2014.10.FOCUS12367
Barbara J. Fisher, Chen Hu, David R. Macdonald, Glenn J. Lesser, Stephen W. Coons, David G. Brachman, Samuel Ryu, Maria Werner-Wasik, Jean-Paul Bahary, Junfeng Liu, Arnab Chakravarti, Minesh Mehta, Phase 2 Study of Temozolomide-Based Chemoradiation Therapy for High-Risk Low-Grade Gliomas: Preliminary Results of Radiation Therapy Oncology Group 0424 International Journal of Radiation Oncology*Biology*Physics. ,vol. 91, pp. 497- 504 ,(2015) , 10.1016/J.IJROBP.2014.11.012
D. Schiff, P. D. Brown, C. Giannini, Outcome in adult low-grade glioma: the impact of prognostic factors and treatment Neurology. ,vol. 69, pp. 1366- 1373 ,(2007) , 10.1212/01.WNL.0000277271.47601.A1
Roger Stupp, Warren P. Mason, Martin J. van den Bent, Michael Weller, Barbara Fisher, Martin J.B. Taphoorn, Karl Belanger, Alba A. Brandes, Christine Marosi, Ulrich Bogdahn, Jürgen Curschmann, Robert C. Janzer, Samuel K. Ludwin, Thierry Gorlia, Anouk Allgeier, Denis Lacombe, J. Gregory Cairncross, Elizabeth Eisenhauer, René O. Mirimanoff, Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma The New England Journal of Medicine. ,vol. 352, pp. 987- 996 ,(2005) , 10.1056/NEJMOA043330
Deborah A. Forst, Brian V. Nahed, Jay S. Loeffler, Tracy T. Batchelor, Low-Grade Gliomas Oncologist. ,vol. 19, pp. 403- 413 ,(2014) , 10.1634/THEONCOLOGIST.2013-0345